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Oxycodone hydrochloride is a semi-synthetic opioid agonist
that provides very effective relief for moderate to severe pain
in cancer and post-operative patients. Controlled release
oxycodone formulations have been studied to enhance the
therapeutic effect by providing constant release over the whole
dosing interval and improve patient’s convenience by reduc-
ing the frequency of administration as well. The aim of this
study was to develop once-a-day controlled release formula-
tions containing oxycodone hydrochloride by modulating the
release barrier in bi-layered tablet and investigating the IVIVC.
Controlled release formulations containing 20 mg of
oxycodone were prepared by bi-layered tablet technology con-
sisting of drug contained layer and barrier layer. In vitro drug
dissolution test was conducted according to USP Apparatus 2
at 150 rpm in pH 6.8 media and analyzed the released drug
using reversed phase HPLC at a wavelength of 230 nm. Three
CR formulations having different drug releasing profiles were
orally administrated to six subjects of Beagle dog. The plasma
samples were analyzed by LC-MS/MS and calculated pharma-
cokinetic parameters. IVIVC was investigated using fraction
dissolved and fraction absorbed data from three different for-
mulations. The bi-layered tablets were successfully
manufactured by simple direct compression and showed more
continuous drug release kinetics than the monolayer tablets.
In vitro dissolution profiles were controlled by the viscosity of
hypromellose in the barrier layer. In the pharmacokinetic study
of three different CR tablets, modulating the release rate by
different barrier layers affected the absorption of oxycodone.
Fraction dissolved and fraction absorbed were well corre-
lated with superior correlation coefficients (0.9930, 0.9949, and
0.9688). Bi-layered controlled release formulations consisting
of drug contained layer and barrier layer including hypromellose
were established with respect to well controlled dissolution pro-
files and IVIVC in Beagle dog model.The findings of the present
study provide the potential of once-a-day controlled released
oxycodone hydrochloride.
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